Unicycive Therapeutics, Inc.UNCY
Price (close)
$4.81
Market cap
$134.0M
P/E
—
Revenue (TTM)
—
Net income
-$35.2M
Dividend yield
—
1-year total return
28.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Unicycive Therapeutics, Inc. does.
focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial
focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable
of accelerating the advancement of promising therapies from discovery to commercialization. Currently, our two programs are focused on
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $951,000 | $675,000 | — | — |
| Net income | -$2.3M | -$10.0M | -$18.1M | -$30.5M | -$36.7M | -$26.6M |
| Free cash flow | — | -$5.8M | -$15.7M | -$18.3M | -$28.6M | -$31.3M |
More on UNCY.
- Unicycive Therapeutics, Inc. summary
- Unicycive Therapeutics, Inc. financial statements
- Unicycive Therapeutics, Inc. key metrics
- Unicycive Therapeutics, Inc. health scores and style box
- Unicycive Therapeutics, Inc. earnings
- Unicycive Therapeutics, Inc. dividends
- Unicycive Therapeutics, Inc. valuation
- Unicycive Therapeutics, Inc. ownership and insiders
- Unicycive Therapeutics, Inc. peers
Figures from Unicycive Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.